- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00874965
Electrostimulation, Skeletal Muscle Function, and Exercise Capacity in Chronic Obstructive Pulmonary Disease (COPD) (ESTIM)
Study of the Benefits of Lower Limb Electrostimulation Training on Muscular Parameters and Minute Ventilation During Exercise in Severe and Deconditioned COPD Patients.
This study was designed to test the following hypothesis:
The benefit of electrostimulation training will be greater than sham stimulation training in term of muscle strength and mass (muscle hypertrophy), exercise tolerance, reduction of ventilation during exercise and quality of life in COPD patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Because it has little impact on ventilatory requirements and dyspnea, muscle electrostimulation appears as a promising alternative to general physical reconditioning in advanced COPD and its feasibility has been confirmed in this population. However, the physiological mechanisms underlying the proposed benefits of electrostimulation training have not been explored.
Objective: To evaluate in COPD patients the physiological mechanisms of changes in exercise tolerance after electrostimulation training.
Method: We propose to conduct a controlled, randomized and double blind clinical trial comparing the efficacy of muscle electrostimulation training of the lower limbs to sham training in 24 patients with COPD. Patients are included in either 6 weeks of electrostimulation training (active treatment group) or 6 weeks of sham electrostimulation. Before and after training, patients perform endurance shuttle walking test, muscle function testing, muscle biopsy, blood sampling and health-related quality of life questionnaire.
Planning analysis: The main outcome will be change in the strength of the quadriceps over the 6-week electrostimulation program. The other end-points will be mid-thigh and calf muscle cross-sectional area, lower limb muscle endurance, ventilation, dyspnea, leg fatigue, operational lung volumes at iso-time and walking time during an endurance shuttle walk, muscle hypertrophying/atrophying pathways and muscle aerobic capacity. For each group, pre- and post-training comparisons will be made using a repeated measures design. The magnitude of the pre- and post-training changes will also compared between both groups with a two-way ANOVA (group, training effect) with repeated measures on the second factor (training effect). A p value < 0.05 will be considered statistically significant.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Quebec city, Quebec, Canada, G1V4G5
- Hôpital Laval
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- COPD
- FEV1 < 60% predicted value and FEV1/ FVC < 70%
- 6-minute walking distance < 400 m
Exclusion Criteria:
- Patients suffering from cardiovascular, neurological, skeletal muscle, or any other condition that could alter their capacity to perform the exercise test
- Patients taking systemic corticosteroids on a daily basis (patients having received systemic steroids for the treatment of up to two exacerbations in the preceding year and those on inhaled steroids will be allowed)
- Patients with room air PaO2 < 60 mm Hg will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: ES
Electrostimulation
|
50Hz; 0.4 ms; 30 min; 5 times / week
|
|
Placebo Comparator: Sham ES
Sham stimulation
|
30 min; 5 times / week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in the strength of the quadriceps over the 6-week electrostimulation program.
Time Frame: 6 to 8 weeks
|
6 to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Ventilation at iso-time during an endurance shuttle walkMuscle
Time Frame: 6 to 8 weeks
|
6 to 8 weeks
|
|
hypertrophying/atrophying pathways
Time Frame: 6 to 8 weeks
|
6 to 8 weeks
|
|
Muscle aerobic capacity: fibre-typing, oxydative enzymes, muscle capillarization
Time Frame: 6 to 8 weeks
|
6 to 8 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CER20105
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)
-
Ryme Medical, Inc.Not yet recruitingCOPD | Lung Disease, Chronic Obstructive | COPD Patients | COPD Acute Exacerbation | COPD (Chronic Obstructive Pulmonary Disease) | Lung Disease Airways | COPD Exacerbations
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Morair Medtech, LLCRecruitingEmphysema | COPD | Emphysema or COPD | COPD (Chronic Obstructive Pulmonary Disease) | Emphysema, PulmonaryAustria, Germany, Netherlands
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Barron Associates, Inc.National Heart, Lung, and Blood Institute (NHLBI); University of VirginiaNot yet recruitingCOPD | COPD - Chronic Obstructive Pulmonary DiseaseUnited States
Clinical Trials on Electrostimulation
-
Rennes University HospitalCompletedChronic Renal Failure (CRF)France
-
Tatiane Gomes de AraujoUnknownOveractive Bladder | Parkinson DiseaseBrazil
-
Janaina Mayer de Oliveira NunesTerminatedUrinary Bladder, Overactive
-
Centre Hospitalier Universitaire de NiceCompletedFacioscapulohumeral Muscular DystrophyFrance
-
Hospital de TerrassaUnknown
-
Saliwell Ltd.McGill University; Charite University, Berlin, Germany; University of Brasilia; Indiana University and other collaboratorsCompleted
-
University of Sao Paulo General HospitalRecruitingAtrophy, MuscularBrazil
-
Centro de Atenção ao Assoalho PélvicoRecruitingWomen | Urgent Urinary Incontinence | Transcutaneous Electrical Nerve Stimulation | Bladder HyperactiveBrazil
-
Fundacion para la Investigacion Biomedica del Hospital...CompletedFasciitis, PlantarSpain
-
Medical University of WarsawUnknown